Erythromer

ErythroMer is a blood substitute in development funded by the NIH and Department of Defense.[1] It is novel in that unlike other blood substitutes, Perfluorocarbon-Based Oxygen Carriers (PBOCs) and Cell-Free Hemoglobin Based Carriers (HBOCs), it is stored lyophilized and reconstituted when needed in emergency situations.[2] The product is stable for several months.

The development of this technology was done at Washington University at St. Louis and UIUC.[3] Trials have been successful in rats, mice, and rabbits, and human trials are planned.[4]

References

  1. ↑ "Grants and Contracts | Anesthesia Faculty Scholarship Newsletter | Perelman School of Medicine at the University of Pennsylvania". Med.upenn.edu. 2016-09-30. Retrieved 2016-12-03.
  2. ↑ "5 questions as the world's top blood experts convene". Statnews.com. Retrieved 2016-12-03.
  3. ↑ "ErythroMer Blood Substitute | Washington University in St. Louis website=Otm.wustl.edu". Retrieved 2016-12-03.
  4. ↑ "1027 Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results". Ash.confex.com. Retrieved 2016-12-03.


This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.